云顶新耀:4年后营收150亿;第三款王炸新药获批

药圈观察局
Feb 06

看之前记得先点个关注,欢迎投稿共创。药圈观察局,最新观察:‌本文为共创内容,作者:#药圈观察局2组2月6日,云顶新耀自身免疫核心产品维适平(精氨酸艾曲莫德片)正式获批上市。维适平是一种新一代高选择性鞘氨醇-1-磷酸(S1P)受体调节剂,通过调控淋巴细胞迁移,从源头控制肠道炎症,并促进黏膜愈合。其核心优势在于:每日一次口服,兼具便捷性与快速起效能力;以深度黏膜愈合为关键治疗目标,直击临床痛点。据悉,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10